Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Single-Blind, Placebo-Controlled, Sequential Treatment, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of CPC-201 in Patients With Alzheimer's Disease Type Dementia

NCT02185053 is registered in ClinicalTrials.gov with Chase Pharmaceuticals Corporation, an affiliate of Allergan plc as lead sponsor.

NCT NCT02185053
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02185053 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Single-Blind, Placebo-Controlled, Sequential Treatment, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of CPC-201 in Patients With Alzheimer's Disease Type Dementia
Lead sponsor
Chase Pharmaceuticals Corporation, an affiliate of Allergan plc
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2014
Completion date
July 31, 2016
Enrollment
41 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease